Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 32 Neoplasms 6 Carcinoma, Non-Small-Cell Lung 4 Prostatic Neoplasms 3 Neoplasm Metastasis 3 Carcinoma, Ovarian Epithelial 3 Pancreatic Neoplasms 2 Lung Neoplasms 2 Kidney Neoplasms 2 Fallopian Tube Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Renal Cell 2 Breast Neoplasms, Male 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Solid Malignancies 1 Sarcoma 1 Recurrent Uterine Corpus Sarcoma 1 Recurrence 1 Pain 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Liver Neoplasms 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Glioblastoma 1 Endometrial Adenocarcinoma 1

Interventions

Carboplatin 23 Cisplatin 19 pembrolizumab 14 Paclitaxel 12 Gemcitabine 12 Pemetrexed 11 130-nm albumin-bound paclitaxel 9 Everolimus 8 Cetuximab 8 Fluorouracil 7 Axitinib 6 osimertinib 5 durvalumab 5 Sunitinib 5 Radiotherapy 5 Erlotinib Hydrochloride 5 Docetaxel 5 Cyclophosphamide 5 Albumin-Bound Paclitaxel 5 Sorafenib 4 Radiation 4 Nivolumab 4 Ipilimumab 4 vosaroxin 3 Radiotherapy, Intensity-Modulated 3 Octreotide 3 Irinotecan 3 Bevacizumab 3 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3 pralsetinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Carcinoma × ixabepilone × Clear all

NCT02915744 2023-04-14

ATTAIN

Nektar Therapeutics

Phase 3 Completed

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡